Background. Clostridium difficile infections (CDI) result in considerable morbidity and mortality. With more than 336,000 CDI cases reported in 2009 and the emergence of the hypervirulent NAP1/BI/027 C. difficile strain, there is great incentive to identify effective antimicrobial treatment options. Fidaxomicin is a novel agent with bactericidal activity against C. difficile, and its use may help achieve CDI resolution and prevent recurrence. The purpose of this study was to examine the use of fidaxomicin at the St. Vincent Indianapolis Hospital and to assess the clinical and economic benefits its use provides.
Methods. This retrospective matched cohort study evaluated patients with CDI who received fidaxomicin or vancomycin from March 2012-October 2013. Each adult participant who had received fidaxomicin was matched and compared to two participants who had received vancomycin. Participants were excluded if they had received either medication for less than two days and/or were pregnant during treatment. The primary objective was clinical efficacy, defined by cure or clinical improvement of CDI at discharge and neither a record of death nor readmission to a St. Vincent Health hospital thirty days post discharge. Secondary objectives included length of total hospital stay, length of hospital stay after initiation of CDI treatment, number of readmissions, number of readmissions related to CDI, adverse events, presence/development of CDI sequelae, and actual variable direct and total hospital costs.
Results. Twenty-six fidaxomicin patients met inclusion criteria and were matched to 46 vancomycin patients. Both cohorts were statistically similar at baseline in all areas except probiotic use (62% fidaxomicin vs 15% vancomycin, p < 0.001). There was no significant difference in clinical efficacy rates between the two cohorts (46% fidaxomicin vs 50% vancomycin, p = 0.809). Patients in the fidaxomicin cohort were found to have a longer average length of stay (22.5 days vs 13.8 days, p = 0.015). Other secondary outcomes were not significantly different.
Conclusion. Fidaxomicin did not show a difference in our composite outcome when compared to vancomycin in our patient population receiving therapy for CDI.
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